Siemens Healthineers : Q2 review – stronger Imaging performance, weaker Diagnostics
>Positive second quarter, but unexpected decline of book-to-bill - Q2 revenues of € 5,346m (-3.6% y-o-y) were 2%/3% ahead of ODDO BHF/consensus estimates. The comparable sales decline was 2.5% (vs -4.1%/-1.7% expected) impacted by lower revenues from the rapid COVID-19 antigen test. Excluding the test, comparable sales growth would have been at a strong 11.2%. The equipment book-to-bill was at a level of 1.01, down from 1.36 at the Q1 results. Adjusted EBIT of € 681m ...Siemens Healthineers AG is a Germany-based company that supplies technology to the healthcare industry. The Company offers a wide range of products and services in the fields of diagnostic and therapeutic imaging, laboratory and point of care diagnostics, and molecular medicine. It provides medical technology and software solutions, as well as clinical consulting services. Additionally, the Company is developing its digital health and enterprise services trough expanding precision medicine, transforming care delivery, improving patient experience, and digitalizing healthcare to enable healthcare providers to increase value. Siemens AG is a majority shareholder of the Company. The Company is active worldwide.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.